[2026 National Assembly Audit: New Medicines and Digital Healthcare]
- Health and Welfare Committee -

The 2026 National Assembly Audit raised key questions about reimbursement assessments for new medicines, rules governing telemedicine and medicine delivery, and regulatory safeguards for GLP-1 treatments.

For pharmaceutical companies and digital healthcare providers, these debates could shape market access, pricing, prescribing requirements, and service delivery models.

In the fifth chapter of GR Korea's 2026 National Assembly Audit series, we examine these policy developments and what healthcare businesses should watch as Korea reviews its approach to healthcare access and patient safeguards.

Read the full newsletter below.